Discontinuation or Interruption of Antiretroviral Therapy  (Last updated April 8, 2015; last reviewed April 8, 2015)

Discontinuation of antiretroviral therapy (ART) may result in viral rebound, immune decompensation, and clinical progression.\(^1\)\(^-\)\(^5\) Thus, planned interruptions of ART are not generally recommended. However, unplanned interruption of ART may occur under certain circumstances as discussed below.

**Short-Term Therapy Interruptions**

Reasons for short-term interruption (days to weeks) of ART vary and may include drug toxicity; intercurrent illnesses that preclude oral intake, such as gastroenteritis or pancreatitis; surgical procedures; or interrupted access to drugs. Stopping ART for a short time (i.e., less than 1 to 2 days) because of a medical/surgical procedure can usually be done by holding all drugs in the regimen. Recommendations for some other scenarios are listed below:

**Unanticipated Short-Term Therapy Interruption**

*When a Patient Experiences a Severe or Life-Threatening Toxicity or Unexpected Inability to Take Oral Medications:*

- All components of the drug regimen should be stopped simultaneously, regardless of drug half-life.

**Planned Short-Term Therapy Interruption (Up to 2 Weeks)**

*When All Regimen Components Have Similar Half-Lives and Do Not Require Food for Proper Absorption:*

- All drugs may be given with a sip of water, if allowed; otherwise, all drugs should be stopped simultaneously. All discontinued regimen components should be restarted simultaneously.

*When All Regimen Components Have Similar Half-Lives and Require Food for Adequate Absorption, and the Patient Cannot Take Anything by Mouth for a Short Time:*

- Temporary discontinuation of all drug components is indicated. The regimen should be restarted as soon as the patient can resume oral intake.

*When the Antiretroviral Regimen Contains Drugs with Different Half-Lives:*

- Stopping all drugs simultaneously may result in functional monotherapy with the drug with the longest half-life (typically a non-nucleoside reverse transcriptase inhibitor [NNRTI]), which may increase the risk of selection of NNRTI-resistant mutations. Some experts recommend stopping the NNRTI first and the other antiretroviral drugs 2 to 4 weeks later. Alternatively, the NNRTI may be replaced with a ritonavir- or cobicistat-boosted protease inhibitor (PI/r or PI/c) for 4 weeks. The optimal time sequence for staggered discontinuation of regimen components, or replacement of the NNRTI with a PI/r or PI/c, has not been determined.

**Planned Long-Term Therapy Interruptions**

Planned long-term therapy interruptions are not recommended outside of controlled clinical trials (AI). Several research studies are evaluating approaches to a functional (virological control in the absence of therapy) or sterilizing (virus eradication) cure of HIV infection. Currently, the only way to reliably test the effectiveness of these strategies may be to interrupt ART and closely monitor viral rebound over time in the setting of a clinical trial.

If therapy must be discontinued, patients should be aware of and understand the risks of viral rebound, acute retroviral syndrome, increased risk of HIV transmission, decline of CD4 count, HIV disease progression, development of minor HIV-associated manifestations such as oral thrush or serious non-AIDS complications (e.g., renal, cardiac, hepatic, or neurologic complications), development of drug resistance, and the need for
chemoprophylaxis against opportunistic infections as a result of CD4 decline. Patients should be counseled about the need for close clinical and laboratory monitoring during therapy interruptions.

References


